Clinical Trials

921 enrolled 48 charts 1 FDA

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT02000622 2026-02-13

OlympiAD

302 enrolled 26 charts 1 FDA

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

270 enrolled 1 FDA

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04035486 2025-10-10

FLAURA2

587 enrolled 44 charts 1 FDA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

731 enrolled 1 FDA

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

253 enrolled 21 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02492711 2025-03-17

SOPHIA

624 enrolled 17 charts 1 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 2 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

452 enrolled 35 charts 1 FDA